[go: up one dir, main page]

MX2019006552A - Terapia génica para mucopolisacaridosis de tipo i. - Google Patents

Terapia génica para mucopolisacaridosis de tipo i.

Info

Publication number
MX2019006552A
MX2019006552A MX2019006552A MX2019006552A MX2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A
Authority
MX
Mexico
Prior art keywords
mucopolysaccharidosis
type
gene therapy
methods
provides compositions
Prior art date
Application number
MX2019006552A
Other languages
English (en)
Inventor
A Goss Kendrick
B Parsons Geoffrey
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MX2019006552A publication Critical patent/MX2019006552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)

Abstract

La invención proporciona composiciones y métodos para el tratamiento de la MPS I.
MX2019006552A 2016-12-06 2017-12-06 Terapia génica para mucopolisacaridosis de tipo i. MX2019006552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430795P 2016-12-06 2016-12-06
PCT/US2017/064913 WO2018106807A1 (en) 2016-12-06 2017-12-06 Gene therapy for mucopolysaccharidosis, type i

Publications (1)

Publication Number Publication Date
MX2019006552A true MX2019006552A (es) 2019-10-15

Family

ID=62491308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006552A MX2019006552A (es) 2016-12-06 2017-12-06 Terapia génica para mucopolisacaridosis de tipo i.

Country Status (13)

Country Link
US (1) US20220339296A1 (es)
EP (1) EP3551750A4 (es)
JP (1) JP2019536484A (es)
KR (1) KR20190089988A (es)
CN (1) CN110214182A (es)
AU (1) AU2017370662A1 (es)
BR (1) BR112019011635A2 (es)
CA (1) CA3046079A1 (es)
IL (1) IL267057A (es)
MA (1) MA47847A (es)
MX (1) MX2019006552A (es)
RU (1) RU2019120721A (es)
WO (1) WO2018106807A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071695A2 (pt) 2016-04-20 2019-02-19 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas composições e métodos para a expressão gênica acentuada de pklr
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN111163810B (zh) 2017-10-16 2024-09-10 能源环境和技术研究中心O.A.,M.P. 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体
SG11202100025QA (en) * 2018-07-30 2021-01-28 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Methods for gene modification of hematopoietic cells
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
AU2022289260A1 (en) * 2021-06-08 2023-12-07 Touchlight IP Limited Lentiviral vector
WO2024201066A1 (en) * 2023-03-31 2024-10-03 Dawn Therapeutics Limited Novel vector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US20110294114A1 (en) * 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
JP6143231B2 (ja) * 2011-06-10 2017-06-07 ブルーバード バイオ， インコーポレイテッド 副腎脳白質ジストロフィおよび副腎脊髄神経障害のための遺伝子療法ベクター
US9695443B2 (en) * 2012-05-25 2017-07-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Vector for the selective silencing of a gene in astrocytes
EP3567112A1 (en) * 2013-06-13 2019-11-13 Translate Bio, Inc. Messenger rna based viral production
US11326183B2 (en) * 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same

Also Published As

Publication number Publication date
RU2019120721A (ru) 2021-01-11
EP3551750A1 (en) 2019-10-16
JP2019536484A (ja) 2019-12-19
IL267057A (en) 2019-08-29
BR112019011635A2 (pt) 2019-11-12
KR20190089988A (ko) 2019-07-31
US20220339296A1 (en) 2022-10-27
WO2018106807A1 (en) 2018-06-14
AU2017370662A1 (en) 2019-06-27
MA47847A (fr) 2020-01-29
CN110214182A (zh) 2019-09-06
CA3046079A1 (en) 2018-06-14
EP3551750A4 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
GEAP202014670A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
PH12017501999A1 (en) K-ras modulators
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2021006326A (es) Inhibidores de pcna.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
AU2015315168A8 (en) Targeted mutagenesis in spirulina